Could Ozempic Lower Alzheimer’s Risk?

As the popularity of Ozempic continues to surge for its use in managing type 2 diabetes and supporting weight loss, new questions are emerging about the drug’s potential role in preventing or slowing Alzheimer’s disease.

To help separate fact from speculation, Hadi Finnerty, Senior Manager of Education & Community Volunteers at the Alzheimer’s Association Illinois Chapter, joined WGN radio host Lisa Dent to discuss the latest research and what it might mean for the future of Alzheimer’s treatment https://tinyurl.com/kpmn69r6.

Recent studies have hinted that semaglutide—the active ingredient in Ozempic—may have some impact on reducing Alzheimer’s-related brain changes. However, Finnerty urged caution. “While these early findings are certainly worth watching, the studies we’re seeing right now have very small sample sizes,” she told Dent. “They’re not large or long-term enough to give us confidence in the results just yet.”

Ozempic, a GLP-1 receptor agonist, has shown promise in animal models for reducing brain inflammation and potentially slowing the accumulation of amyloid plaques, a hallmark of Alzheimer’s disease. But as Finnerty emphasized, translating those results to real-world human outcomes remains a significant challenge.

Finnerty stressed that while the idea of a widely available medication reducing Alzheimer’s risk is exciting, people should not see Ozempic as a preventive treatment for cognitive decline—at least not yet. “There’s a difference between early biological signals and actual clinical benefits for people living with or at risk for Alzheimer’s,” she explained.

She encouraged listeners to stay informed but cautious, especially as buzz around the drug continues to grow in media and online communities.

Larger, more rigorous clinical trials are needed before doctors can say with any certainty whether Ozempic or similar medications can truly help in the fight against Alzheimer’s. In the meantime, Finnerty underscored the importance of established brain health practices—such as regular exercise, healthy diet, social engagement, and controlling chronic conditions like diabetes and high blood pressure.

The Alzheimer’s Association continues to track developments in this area and supports research that explores all promising avenues for treatment and prevention.

For more information, support services, or to learn how to get involved in clinical trials, visit www.alz.org/illinois or call their 24/7 Helpline at 800-272-3900.